The State of Weight-Loss Drugs

Nvidia announced its new CPU at an event in Taipei and Jon, Rachel, and Matt talked about why potential customers may be interested in buying as well as the potential impacts to primary CPU players such as Intel and AMD. The team also talks about Berkshire Hathaway’s homebuilder ...  Show more

Token consumption grew 17 times last year — not 17%, 17 times. So why are some investors still underexposed to the biggest structural shift in a generation? Motley Fool Contributing Analyst Rachel Warren talks with Jay Jacobs, US Head of Equity ETFs at BlackRock, about the firm's ...  Show more

This time, we have a very special episode I recorded with my close friend Kevin Rose in person at his house. We trade our latest discoveries, and I think it’s one of our best. Tons o ...

Dr. Marty Makary, a renowned surgeon and professor at Johns Hopkins, public health expert, and a two-time New York Times bestselling author, joins Scott to discuss his latest book, Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health. They go over topics inc ...  Show more

Shares in Eli Lilly surged on Friday  after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine. Shares of the drug’s originator Chugai ...  Show more

David Senra is the host of the Founders podcast. For the past nine years, David has intensely studied the life and work of hundre ...